PerkinElmer
check quantity

ProSense 750 EX Fluorescent Imaging Agent

Proteases perform a fundamental role in protein regulation. Altered activity of lysosomal cathepsins, a class of protease, can indicate many disease-related processes, such as those involved in cancer, inflammation, arthritis, cardiovascular and many others. The ability to detect and quantify normal as well as altered protease cathepsin activity in vivo allows the progress and severity of these disease states to be tracked and interrogated over time. PerkinElmer’s ProSense® imaging agents are protease activatable NIR fluorescent probes that are optically silent in their intact state and become highly fluorescent following protease-mediated cleavage and activation. ProSense is available in 3 formats; 680, 750 EX, and 750 FAST.

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
SKU Display Name
List Price
Your Price
Quantity
NEV10003
ProSense 680 Fluorescent Imaging Agent
601.00 USD
 
more
NEV10001EX
ProSense 750 EX Fluorescent Imaging Agent
643.00 USD
 
more
NEV11171
ProSense 750 FAST Fluorescent Imaging Agent
710.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

ProSense 750 EX is in our family of “Smart” cathepsin probes, which become fluorescent only after enzymatic cleavage, keeping background down and allowing detection of activated protease. It also offers a secondary wavelength for ProSense, to allow greater flexibility for multiplexing with probes of other excitation/emission wavelengths. 24h imaging at 750 nm.

Specifications

Fluorescent Agent Type Activatable
Optical Imaging Classification Fluorescence Imaging
Product Brand Name ProSense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer
Unit Size 1 Vial (10 doses)
Wave Length 750 nm
Resources, Events & More
  • All

Application Note

In Vivo Imaging of Atherosclerosis Disease Using FMT

Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles associated with atherosclerotic disease, in vivo, would enable a robust additional understanding and analysis of disease progression and therapeutic response in research and drug development. We report the utility of the near infrared (NIR) protease-sensing, ProSense® 750 Fluorescent Pre-clinical Imaging Agent, in combination with the FMT® 2500 Quantitative Pre-clinical Imaging System for the non-invasive quantitative measurement of atherosclerotic disease biology and related response to therapy in apolipoprotein (apo) E-deficient mice in vivo. FMT (Fluorescence Molecular Tomography) imaging measured significant increases in aortic region protease activity with a range of values that were comparable to the range seen in the ex vivo aortic arches assessed by fluorescence reflectance imaging (FRI).

PDF 1 MB
Multiplex 2D Imaging of NIR Molecular Imaging Agents on the IVIS SpectrumCT and FMT 4000

Epifluorescence (2D) imaging of superficially implanted mouse tumor xenograft models offers a fast and simple method for assessing tumor progression or response to therapy. This approach for tumor assessment requires the use of near infrared (NIR) imaging agents specific for different aspects of tumor biology, and this Application Note highlights the ease and utility of multiplex NIR fluorescence imaging to characterize the complex biology within tumors growing in a living mouse.

PDF 4 MB
Noninvasive In Vivo Quantitation of Asthma Severity Using FMT

Asthma is an inflammatory disease process characterized by reversible airway obstruction and airway hyperresponsiveness. This disease process is driven by activated T lymphocytes and eosinophils that are recruited to the lung upon inhalation of triggering allergens. These cells release inflammatory mediators, activate mast cells and epithelial cells and stimulate mucus secretion, ultimately leading to airway obstruction. The incidence and severity of asthma is increasing worldwide, elevating the need for clinically relevant in vivo animal models that can be used to improve the understanding of asthma biology and the development of effective therapeutics. Here we illustrate the use of PerkinElmer’s FMT® 2500LX Quantitative Pre-clinical Imaging System in combination with ProSense® 680 Fluorescent Pre-clinical Imaging Agent, a near-infrared, protease-activatable agent, for the noninvasive in vivo imaging and quantitation of pulmonary inflammation.

PDF 488 KB

Technical Note

ProSense 750 EX (Protocol)

ProSense 750 EX activatable fluorescent imaging agent Protocol

PDF 258 KB
ProSense® 750 EX (Data Sheet)

ProSense®750 EX is a protease activatable fluorescent in vivo imaging agent that is activated by key disease associated proteases such as Cathepsin B, L, S and Plasmin. ProSense®750 EX is optically silent in its unactivated state and becomes highly fluorescent following protease-mediated activation.

PDF 315 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB